Guidelines on the management of ascites in cirrhosis

Gut

Volumn 55, Issue SUPPL. 6, 2006, Pages

  Moore, K P ^a   Aithal, G P ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMYLASE; ANTIBIOTIC AGENT; BUMETANIDE; CEFOTAXIME; CEPHALOSPORIN; CIPROFLOXACIN; DIURETIC AGENT; FUROSEMIDE; NORFLOXACIN; PROTEIN; SPIRONOLACTONE;

ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ANTIBIOTIC THERAPY; ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; CLINICAL TRIAL; CYTOLOGY; DRUG EFFICACY; DRUG MECHANISM; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; PARACENTESIS; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SODIUM BLOOD LEVEL; SODIUM RETENTION; WATER RETENTION;

ASCITES; ASCITIC FLUID; BED REST; CHRONIC DISEASE; DIET, SODIUM-RESTRICTED; DIURETICS; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPONATREMIA; LEUKOCYTE COUNT; LIVER CIRRHOSIS; NEUTROPHILS; PARACENTESIS; PERITONITIS; PORTASYSTEMIC SHUNT, SURGICAL; PROGNOSIS; SURVIVAL RATE; WATER-ELECTROLYTE IMBALANCE;

EID: 33749173318     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.099580     Document Type: Review

References (156)

1. Kim WR, Brown JR, Terrault NA, et al. Burden of liver disease in the United States: summary of the workshop. Hepatology 2002;36:227-42.
2. Gines P, Quintero E, Arroyo V, Teres J, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:12-18.
3. Powell WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis of the liver. Am J Med 1968;44:406-20.
4. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
5. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoconstrictive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-7.
6. Runyon BA. Ascites. In: Schiff L, Schiff ER, eds. Diseases of the liver, 7th Edn. Philadelphia: Lippincott, 1993:990-1015.
7. Fisher NC, Hanson J, Phillips A, et al. Mortality from liver disease in the West Midlands, 1993-2000: observational study. BMJ 2002;325:312-13.
8. British Society of Gastroenterology Care of patients with gastrointestinal disorders in the United Kingdom. An evidence based strategy for the future. London: British Society of Gastroenterology, March 2005.
9. Philips B, Ball C, Sackett D, et al. Oxford Centre for evidence-based medicine http://cebm.net/levels_of_evidence.asp#levels (last accessed 11 August 2006).
10. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66.
11. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
12. Arroyo V, Gines P, Planas R, et al. Pathogenesis, diagnosis, and treatment of ascites in cirrhosis. In: Bircher J, Benhamou J-P, McIntyre N, et al, eds. Oxford textbook of clinical hepatology. New York: Oxford University Press, Inc, 1999:697-731.
13. Dudley FJ. Pathophysiology of ascites formation. Gastroenterol Clin North Am 1992;21:215-35.
14. Gines P, Fernandez-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997;17:175-89.
15. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296-303.
16. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
17. Bernardi M, Santini C, Trevisani F, et al. Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 1985;26:629-35.
18. Bernardi M, Fornale L, Di Marco C, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995;22:309-18.
19. Wong F, Liu P, Tobe S, et al. Central blood volume in cirrhosis: measurement with radionucleotide angiography. Hepatology 1994;19:312-21.
20. Arroyo V, Gines P, Rimola A, et al. Renal function abnormalities, prostaglandins and effects of non-steroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986;81(suppl 2B):104-22.
21. Wilkinson SP, Jowett TP, Slater JD, et al. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci 1979;56:169-77.
22. Wilkinson SP, Williams R. Renin-angiotensin-aldosterone system in cirrhosis. Gut 1980;21:545-54.
23. Lang F, Tschernko E, Schulze E, et al. Hepatorenal reflex regulating renal kidney function. Hepatology 1991;12:590-4.
24. Jalan R, Forrest EH, Redhead DN, et al. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664-70.
25. Jalan R, Hayes PC. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 2000;46:527-33.
26. Runyon BA. Paracentesis of ascites fluid: a safe procedure. Arch Int Med 1986;146:2259-61.
27. McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracenetesis in patients with mild coagulation abnormalities. Transfusion 1991;13:164-71.
28. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-56.
29. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
30. Bac D-J, Siersema PD, Mulder PGH, et al. Spontaneous bacterial peritonitis: outcome and predictive factors. Eur J Gastroenterol Hepatol 1993;5:635-40.
31. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000;32:142-53.
32. Bar-Meir S, Lerner E, Conn HO. Analysis of ascitic fluid in cirrhosis. Dig Dis Sci 1979;24:136-44.
33. DeSitter L, Rector WG Jr. The significance of bloody ascites in patients with cirrhosis. Am J Gastroenterol 1984;79:136-8.
34. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988;95:1351-5.
35. Manohar A, Simjee AA, Pettengill KE. Symptoms and investigative findings in 145 patients with tuberculous peritonitis diagnosed by peritoneoscopy and biopsy over a five year period. Gut 1990;31:1130-2.
36. Castellote J, Xiol X, Verdaguer R, et al. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990;85:1605-8.
37. Siersema PD, de Marie S, van Zeijl JH, et al. Blood culture bottles are superior to lysis-centrifugation tubes for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1992;30:667-9.
38. Pawar GP, Gupta M, Satija VK. Evaluation of culture techniques for detection of spontaneous bacterial peritonitis in cirrhotic ascites. Indian J Gastroenterol 1994;13:139-40.
39. Runyon BA, Amillon MR, Akriviadis EA, et al. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990;28:2811-12.
40. Sampliner RF, Iber FL. High protein ascites in patients with uncomplicated hepatic cirrhosis. Am J Med Sci 1974;267:275-9.
41. Wilson JAP, Suguitan EA, Cassidy WA, et al. Characteristics of ascitic fluid in the alcoholic cirrhotic. Dig Dis Sci 1979;24:645-8.
42. Hoefs JC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 1983;102:260-73.
43. Rector WG Jr, Reynolds TB. Superiority of the serum-ascites albumin difference over the ascites total protein concentration in separation of 'transudative' and 'exudative' ascites. Am J Med 1984;77:83-5.
44. Shakil AO, Korula J, Kanel GC, et al. Diagnostic features of tuberculous peritonitis in the absence and presence of chronic liver disease: a case-control study. Am J Med 1996;100:179-85.
45. Mauer K, Manzione NC. Usefulness of the serum-ascites albumin gradient in separating transudative from exudative ascites: another look. Dig Dis Sci 1988;33:1208-12.
46. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Int Med 1992;117:215-20.
47. Runyon BA. Amylase levels in ascitic fluid. J Clin Gastroenterol 1987;9:172-4.
48. Polak M, Mattosinho Francs LC. Chronic pancreatitis with massive ascites. Digestion 1968;1:296-304.
49. Schindler SC, Schaefer JW, Hull D, et al. Chronic pancreatic ascites. Gastroenterology 1970;59:453-9.
50. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988;8:1104-9.
51. Ring-Larsen H, Henriksen JH, Wilken C, et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. BMJ 1986;292:1351-3.
52. Salo J, Gines A, Anibarro L, et al. Effect of upright posture and physical exercise on endogenous neurohumoral systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 1995;22:479-87.
53. Salo J, Guevara M, Fernandez-Esparrach G, et al. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology 1997;25:1338-42.
54. Gerbes AL. Medical treatment of ascites in cirrhosis. J Hepatol 1993;17:S4-9.
55. Descos L, Gauthier A, Levy VG, et al. Comparison of six treatments of ascites in patients with liver cirrhosis. Hepatogastroenterology 1983;30:15-20.
56. Gauthier A, Levy VG, Quinton A, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomised study. Gut 1986;27:705-9.
57. Soulsby CT, Morgan YM. Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom. BMJ 1999;318:1391.
58. Gregory J, Foster K, Tyler H, et al. The dietary and nutritional survey of British adults. London: HMSO, 1990.
59. Ministry of Agriculture, Fisheries and Food. The dietary and nutritional survey ol British adults - further analysis. London: Ministry of Agriculture, Fisheries and Food, 1994.
60. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Int Med 1982;96:413-17.
61. Gatta A, Caregaro L, Angeli P, et al. Impaired renal water excretion in liver cirrhosis. The role of reduced distal delivery of sodium. Scand J Gastroenterol 1988;23:523-8.
62. Perez-Ayuso RM, Arroyo V, Camps J, et al. Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics. Nephron 1984;36:30-7.
63. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9.
64. Fernandez-Varo G, Ros J, Cejudo-Martin P, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003;38:755-61.
65. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91.
66. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39:187-92.
67. Karim A. Spironolactone metabolism in man revisited. In: Brunner HR, eds. Contemporary trends in diuretic therapy. Amsterdam: Excerpta Medica, 1986:22-37.
68. Eggert RC. Spironolactone diuresis in patients with cirrhosis and ascites. BMJ 1970;4:401-3.
69. Campra JL, Reynolds TB. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Am J Dig Dis 1978;23:1025-30.
70. Fogel MR, Sawhney VK, Neal EA, et al. Diuresis in the ascitic patient: a randomized controlled trial of thee regimens. J Clin Gastroenterol 1981;3(suppl 1):73-80.
71. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in patients with liver cirrhosis and ascites. Gastroenterology 1983;84:961-8.
72. Angeli P, Pria MD, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canreonate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;19:72-9.
73. Li CP, Lee FY, Hwang SJ, et al. Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. Am J Gastroenterol 2000;95:1051-5.
74. Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992;102:1680-5.
75. Yamada S, Reynolds TB. Amiloride (MK-870), a new antikaluretic diuretic. Comparison to other antikaluretic diuretics in patients with liver disease and ascites. Gastroenterology 1970;59:833-41.
76. Herlong HF, Hunter FM, Koff RS, et al. A comparison of bumetanide and furosemide in the treatment of ascites. Cooperative study. J Clin Pharmacol 1981;21:701-5.
77. Gatta A, Angeli P, Caregaro L, et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in non-azotemic cirrhotic patients. Hepatology 1991;14:231-6.
78. Bernardi M, Laffi G, Salvagnini M, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993;13:156-62.
79. Takaya A, Fukui H, Matsumura M, et al. Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment. J Gastroenterol Hepatol 1995;10:30-5.
80. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema Gastroenterology 1986;90:1827-33.
81. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987;93:234-41.
82. Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 1989;321:1632-8.
83. Mirouze D, Zipser RD, Reynolds TB. Effects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983;3:50-5.
84. Planas R, Arroyo V, Rimola A, et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983;84:247-52.
85. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48.
86. Quintero E, Gines P, Arroyo V, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1985;16:611-12.
87. Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients: a safe alternative therapy, J Hepatol 1987;5:102-8.
88. Acharya SK, Balwinder S, Padhee AK, et al. Large volume paracentesis and i.v. dextran to treat tense ascites. J Clin Gastroenterol 1992;14:31-5.
89. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146-51.
90. Gines P, Tito L, Arroyo V, et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology 1988;94:1493-502.
91. Panos MZ, Moore K, Vlavianos P, et al. Single total paracentesis for tense ascites: sequential haemodynamic changes and right atrial size. Hepatology 1990;11:667.
92. Garcia-Compean D, Villarreal JZ, Cuevas HB, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver 1993;13:233-8.
93. Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994;108:709-19.
94. Fernandez-Esparrach G, Guevara M, Boari G, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997;26:614-20.
95. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
96. Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in cirrhotic patients with diuretic-resistant ascites. Am J Gastroenterol 1997;92:394-9.
97. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expander in cirrhotic patients with ascites treated with paracentesis. Gastroenterology 1990;99:1736-44.
98. Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991;13:707-13.
99. Fassio E, Terg R, Landeira G, et al. Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites: Results of randomized study J Hepatol 1992;20:282-8.
100. Arroyo V, Sort P, Gines P, et al. Treatment of ascites by paracentesis. In: Arroyo V, Gines P, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Melbourne: Blackwell Science, 1999:463-79.
101. Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomized controlled pilot trail. Liver Int 2006;26:46-54.
102. Ferral H, Bjarnason H, Wegryn SA, et al. Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology 1993;189:795-801.
103. Ochs A, Rassle M, Haag K, et al. Transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med 1995;332:1192-7.
104. Wang F, Sniderman K, Liu P, et al. The effects of transjugular portosystemic shunt on systemic and renal hemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. Ann Intern Med 1995;122:816-22.
105. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 1995;21:986-94.
106. Crenshaw WB, Gordon FD, McEniff NJ, et al. Severe ascites - efficacy of the transjugular intrahepatic portosystemic stent shunt in treatment Radiology 1996;200:185-92.
107. Nazarian GK, Bjarnason H, Dietz CA Jr, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. Radiology 1997;205:173-80.
108. Forrest EH, Stanley AJ, Redhead DN, et al. Clinical response after intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 1996;10:801-6.
109. Jalan R, Lui HF, Redhead DN, et al. TIPS 10 years on. Gut 2000;46:578-81.
110. Rossle M, Siegerstetter V, Huber V, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS) state of the art. Liver 1998;18:73-89.
111. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: randomized trial. J Hepatol 1996;25:135-44.
112. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
113. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35.
114. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-7.
115. Allard JP, Chan J, Sandokji K, et al. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001;96:2442-7.
116. Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994;20:46-55.
117. Huonker M, Schumacher YO, Ochs A, et al. Cardiac function and hemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743-8.
118. Siegerstetter V, Deibert P, Ochs A, et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001;13:529-34.
119. Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366-9.
120. Jeffries MA, Kazanjian S, Wilson M, et al. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg 1998;4:416-23.
121. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71.
122. Kamath PS, Weisner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
123. Bories P, Garcia-Compean D, Michel H, et al. The treatment of refractory ascites by the LeVeen shunt: a multicenter controlled trial (57 patients). J Hepatol 1986;3:212-18.
124. Wong F. Transjugular intrahepatic portosystemic stent shunt for hepatorenal syndrome and ascites. Digestion 1998;59(suppl 2):41-4.
125. Deschenes M, Dufresne M-P, Bui B, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999;94:1361-5.
126. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991;51:428-30.
127. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-5.
128. Brown RS, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996;62:1788-93.
129. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7.
130. Llovet JM, Planas R, Merillas R, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993;88:388-92.
131. Garcia-Tsao G, Conn HO, Lerner E. The diagnosis of bacterial peritonitis: comparison of pH, lactate concentration and leukocyte count. Hepatology 1985;5:91-6.
132. Yang C-Y, Liaw Y-F, Chu C-M, et al. White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis. Hepatology 1985;5:91-6.
133. Stasscu WN, McCullough AJ, Recou BR, et al. Immediate diagnostic criteria for bacterial infection or ascitic fluid: evaluation of ascitic fluid polymorphonuclear leukocyte count, pH and lactate concentration, alone or in combination. Gastroenterology 1986;90:1247-54.
134. Albillos A, Cuervas-Mons V, Millan I, et al. Ascitic fluid polymorphonuclear cell count and serum in ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology 1990;98:134-40.
135. Angeloni S, Nicolini G, Merli M, et al. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003;98:1844-8.
136. Terg R, Levi D, Lopez P, et al. Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Dig Dis Sci 1992;37:1499-504.
137. Pelletier G, Salmon D, Ink O, et al. Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol 1990;10:327-31.
138. Runyon BA. Monomicrobial non-neutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990;12:710-15.
139. Pelletier G, Lesur G, Ink O, et al. Asymptomatic bacterascites: is it spontaneous bacterial peritonitis? Hepatology 1991;14:112-15.
140. Chu C-M, Chang K-Y, Liaw Y-F. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995;40:561-5.
141. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992;21:257-75.
142. Runyon BA, Akriviadis EA, Sattler FR, et al. Ascitic fluid and serum cefotaxime and desacetylcefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci 1991;36:1782-6.
143. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotics treatment of spontaneous bacterial peritonitis. Gastroenterology 1991;100:1737-42.
144. Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicentre study. Hepatology 1995;21:674-9.
145. Mercader J, Gomez J, Ruiz J, et al. Use of ceftrioxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy 1989;35(suppl 2):23-6.
146. Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990;98:127-33.
147. Wu SS, Lim OS, Chen YY, et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol 2001;34:215-21.
148. Follo A, Llovet JM, Navasa M, et al. Renal impairment following spontaneous bacterial peritonitis in cirrhosis. Incidence, clinical course, predictive factors and prognosis. Hepatology 1994;27:1227-32.
149. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
150. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus nydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627-34.
151. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31.
152. Altman C, Grange JD, Amiot X, et al. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantatation? J Gastroenterol Hepatol 1995;10:47-50.
153. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
154. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
155. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
156. Campillo B, Dupeyron C, Richardet J-P, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998;26:1066-70.